PT - JOURNAL ARTICLE AU - Renk, Hanna AU - Dulovic, Alex AU - Becker, Matthias AU - Fabricius, Dorit AU - Zernickel, Maria AU - Junker, Daniel AU - Seidel, Alina AU - Groß, Rüdiger AU - Hilger, Alexander AU - Bode, Sebastian AU - Fritsch, Linus AU - Frieh, Pauline AU - Haddad, Anneke AU - Görne, Tessa AU - Remppis, Jonathan AU - Ganzemueller, Tina AU - Dietz, Andrea AU - Huzly, Daniela AU - Hengel, Hartmut AU - Kaier, Klaus AU - Weber, Susanne AU - Jacobsen, Eva-Maria AU - Kaiser, Philipp D. AU - Traenkle, Bjoern AU - Rothbauer, Ulrich AU - Stich, Maximilian AU - Tönshoff, Burkhard AU - Hoffmann, Georg F. AU - Müller, Barbara AU - Ludwig, Carolin AU - Jahrsdörfer, Bernd AU - Schrezenmeier, Hubert AU - Peter, Andreas AU - Hörber, Sebastian AU - Iftner, Thomas AU - Münch, Jan AU - Stamminger, Thomas AU - Groß, Hans-Jürgen AU - Wolkewitz, Martin AU - Engel, Corinna AU - Rizzi, Marta AU - Henneke, Philipp AU - Franz, Axel R. AU - Debatin, Klaus-Michael AU - Schneiderhan-Marra, Nicole AU - Janda, Ales AU - Elling, Roland TI - Typically asymptomatic but with robust antibody formation: Children’s unique humoral immune response to SARS-CoV-2 AID - 10.1101/2021.07.20.21260863 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.20.21260863 4099 - http://medrxiv.org/content/early/2021/07/22/2021.07.20.21260863.short 4100 - http://medrxiv.org/content/early/2021/07/22/2021.07.20.21260863.full AB - Background Long-term persistence of antibodies against SARS-CoV-2, particularly the SARS-CoV-2 Spike Trimer, determines individual protection against infection and potentially viral spread. The quality of children’s natural humoral immune response following SARS-CoV-2 infection is yet incompletely understood but crucial to guide pediatric SARS-CoV-2 vaccination programs.Methods In this prospective observational multi-center cohort study, we followed 328 households, consisting of 548 children and 717 adults, with at least one member with a previous laboratory-confirmed SARS-CoV-2 infection. The serological response was assessed at 3-4 months and 11-12 months after infection using a bead-based multiplex immunoassay for 23 human coronavirus antigens including SARS-CoV-2 and its Variants of Concern (VOC) and endemic human coronaviruses (HCoVs), and additionally by three commercial SARS-CoV-2 antibody assays.Results Overall, 33.76% of SARS-CoV-2 exposed children and 57.88% adults were seropositive. Children were five times more likely to have seroconverted without symptoms compared to adults. Despite the frequently asymptomatic course of infection, children had higher specific antibody levels, and their antibodies persisted longer than in adults (96.22% versus 82.89% still seropositive 11-12 months post infection). Of note, symptomatic and asymptomatic infections induced similar humoral responses in all age groups. In symptomatic children, only dysgeusia was found as diagnostic indicator of COVID-19. SARS-CoV-2 infections occurred independent of HCoV serostatus. Antibody binding responses to VOCs were similar in children and adults, with reduced binding for the Beta variant in both groups.Conclusions The long-term humoral immune response to SARS-CoV-2 infection in children is robust and may provide long-term protection even after asymptomatic infection.(Study ID at German Clinical Trials Register: 00021521)Competing Interest StatementNSM was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences Institute at the University of Tuebingen is involved in applied research projects as a fee for services with Luminex. The other authors report no competing interests.Clinical TrialGerman Clinical Trials Register: 00021521Funding StatementThe COVID-19 BaWue study was funded by the Ministry of Science, Research and Arts, Baden-Wuerttemberg, Germany (COVID-19 research framework).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the independent ethics committees of the Medical Faculty Heidelberg (S-294/2020), Medical Faculty Tuebingen (293/2020BO2), University of Ulm 107 (152/20) and University of Freiburg (256/20_201553).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from this study are available upon request.